Core Viewpoint - The article discusses the transformation and strategic adjustments of Ruizhi Pharmaceutical, a veteran in China's CRO industry, under the leadership of Chairman Hu Ruilian, highlighting the company's recovery from significant losses and its focus on innovation and customer needs in a changing market landscape [1][4]. Company Overview - Ruizhi Pharmaceutical, once a leading player in the CRO industry, faced a cumulative loss of 2.2 billion yuan over four years due to management instability and strategic misalignment [3][4]. - In 2025, the company reported a revenue of 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, with a significant improvement in gross margin [1][4]. Strategic Adjustments - The company has established three core strategies: focusing on new modalities such as ADCs, small nucleic acids, and peptides; promoting integrated service models; and expanding globally with new research centers in Boston and a biopharmaceutical park in Malaysia [4][6]. - The shift towards a customer-centric approach emphasizes the importance of meeting client demands for differentiated innovation and high-quality data [5][6]. Market Trends - The Chinese innovative drug market is projected to exceed 400 billion yuan in 2024, indicating a shift from rapid expansion to high-quality development, which impacts the demand for CRO services [4][6]. - The CRO industry is experiencing a transformation driven by client demands for integrated services and advanced technology platforms, particularly for new drug modalities [5][6]. Future Outlook - The integration of AI in drug development is becoming essential, with expectations for CROs to enhance their capabilities in this area [7][8]. - The global pharmaceutical supply chain is being reshaped by geopolitical factors, creating opportunities for Chinese CROs to become reliable partners in global supply chains [9]. - The future success of Chinese CROs hinges on their ability to transition from "Made in China" to "Intelligent Manufacturing in China," leveraging technology and global partnerships [9].

睿智医药科技股份有限公司 审计报告及财务报表 二〇二四年度 信会师报字[2025]第 Z110429 号 码用于证明该审计报告是否由具有执业许可的会计师事务所出具 "册会计师行业统一监管买台（http://acc.mof.gov.cn） 进行查验 您可使用手机"扫一扫"或进入 台(http://acc.mof.gov.cn) 进 睿智医药科技股份有限公司 审计报告及财务报表 (2024年 01月 01 日至 2024 年 12 月 31 日止) | | 目录 | 页次 | | --- | --- | --- | | | 审计报告 | 1-5 | | | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-96 | | 11 | 事务所及注册会计师执业资质证明 | | 6-1-2 立信会计师事务所(特殊普通合1 HINA SHU LUN PAN CERTIFIED PUBLIC A ...

证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司 （Chempartner Pharmatech Co.,Ltd.） （广东省江门市江海区胜利南路 164 号） 2024 年度向特定对象发行股票 募集说明书 （申报稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年九月 声 明 本公司及全体董事、高级管理人员承诺本募集说明书内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应 的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责，投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引 ...

中信证券股份有限公司 关于 睿智医药科技股份有限公司 2024 年度向特定对象发行股票 之 上市保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 2025 年 9 月 睿智医药科技股份有限公司 上市保荐书 声 明 中信证券股份有限公司（以下简称"中信证券"、"保荐人"或"本保荐 人"）及其保荐代表人周游、王栋根据《中华人民共和国公司法》（下称《公司 法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上市公司证 券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市保荐 业务管理办法》（以下简称"《保荐管理办法》"）等有关法律、法规和中国证 券监督管理委员会（以下简称"中国证监会"）的有关规定以及深圳证券交易所 （以下简称"深交所"）的有关业务规则，诚实守信，勤勉尽责，严格按照依法 制定的业务规则和行业自律规范出具本上市保荐书，并保证上市保荐书的真实、 准确、完整。 如无特别说明，本上市保荐书中所涉简称与《睿智医药科技股份有限公司 2024 年度向特定对象发行股票募集说明书》一致。 3-3-1 | | 的控股股东、实际控制人、重要关联方相互提供担保或者 ...

中信证券股份有限公司 关于 睿智医药科技股份有限公司 2024 年度向特定对象发行股票 之 发行保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 2025 年 9 月 睿智医药科技股份有限公司 2024 年度向特定对象发行股票之发行保荐书 声明 本保荐人及保荐代表人根据《中华人民共和国公司法》、《中华人民共和国 证券法》、《上市公司证券发行注册管理办法》、《证券发行上市保荐业务管理 办法》等有关法律、行政法规和中国证券监督管理委员会及深圳证券交易所的规 定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德 准则出具本发行保荐书，并保证所出具文件的真实性、准确性和完整性。 3-1-1 | 声明 1 | | --- | | 目录 2 | | 释义 3 | | 一、普通术语 3 | | 二、专业术语 4 | | 第一节 本次证券发行基本情况 7 | | 一、保荐人项目人员情况 7 | | 二、发行人基本情况 7 | | 三、保荐人及其关联方与发行人及其关联方之间的利害关系及主要业务往来 | | 情况 8 | | 四、保荐人内部审核程序和内核意见 9 | | 五 ...

睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日收到深 圳证券交易所（以下简称"深交所"）出具的《关于受理睿智医药科技股份有限 公司向特定对象发行股票申请文件的通知》（深证上审〔2025〕161 号）。具体内 容详见公司于 2025 年 8 月 27 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于 2024 年度向特定对象发行股票申请获得深圳证券交易所受理的公告》（公告编 号：2025-57） 证券代码：300149 证券简称：睿智医药 公告编号：2025-65 睿智医药科技股份有限公司 关于向特定对象发行股票的募集说明书等 申请文件更新的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2025 年 9 月 12 日 鉴于公司已于 2025 年 8 月 29 日披露了《2025 年半年度报告》，公司会同相 关中介机构对募集说明书、发行保荐书等申请文件中涉及的财务数据及相关内容 进行了更新。具体内容详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的 相关文件。 公司本次向特定 ...

北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮编：100025 电话：(86-10) 5809 1000 传真：(86-10) 5809 1100 北京市竞天公诚律师事务所 关于睿智医药科技股份有限公司 2024 年度向特定对象发行股票的 补充法律意见书（一） 北京市竞天公诚律师事务所 二〇二五年九月 北京市竞天公诚律师事务所 关于睿智医药科技股份有限公司 2024 年度向特定对象发行股票的 补充法律意见书（一） 致：睿智医药科技股份有限公司 根据本所与发行人签订的《法律服务协议》，本所接受发行人的委托，担任 本次发行的专项法律顾问。 针对本次发行，本所于 2025 年 8 月 20 日出具了《北京市竞天公诚律师事务 所关于睿智医药科技股份有限公司 2024 年度向特定对象发行股票的法律意见 书》（以下称"《法律意见书》"）和《北京市竞天公诚律师事务所关于睿智医 药科技股份有限公司 2024 年度向特定对象发行股票的律师工作报告》（以下称 "《律师工作报告》"）。 鉴于自本次发行申请文件首次报送基准日后即 2025 年 4 月 1 日至 2025 年 6 月 30 日期间（以下称"新期间"） ...

Company Overview - Ruizhi Pharmaceutical is located in Guangzhou, Guangdong Province, and was established on January 26, 2000, with its listing date on December 22, 2010 [2] - The company primarily engages in pharmaceutical research and production outsourcing services, with 99.06% of its revenue coming from these services [2] - Other revenue sources include prebiotic products (0.52%), rental income (0.35%), and other income (0.07%) [2] Financial Performance - For the first half of 2025, Ruizhi Pharmaceutical achieved operating revenue of 534 million yuan, representing a year-on-year growth of 14.75% [2] - The net profit attributable to the parent company was 25.38 million yuan, showing a significant year-on-year increase of 140.35% [2] Stock Performance - As of September 12, Ruizhi Pharmaceutical's stock price increased by 2.16%, reaching 13.23 yuan per share, with a total market capitalization of 6.588 billion yuan [1] - The stock has risen 106.07% year-to-date, with a 0.38% increase over the last five trading days and a 23.41% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 165 million yuan on July 29 [1] Shareholder Information - As of August 8, the number of shareholders for Ruizhi Pharmaceutical was 52,500, a decrease of 18.89% from the previous period [2] - The average number of circulating shares per shareholder increased by 23.28% to 9,038 shares [2] - The company has distributed a total of 180 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]

Core Insights - The company aims to become a second choice for drug developers in China, alongside the largest CRO, emphasizing its commitment to innovative drug development [1] - The company reported a revenue of 534 million yuan for the first half of 2025, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, up 140.35% [1] - The company has shifted focus towards new modality drugs, with significant growth in its large molecule business, which achieved a revenue of 105 million yuan, a 54.68% increase [1] Financial Performance - In the first half of 2025, the company achieved a revenue of 534 million yuan, marking a 14.75% increase year-on-year [1] - The net profit for the same period was 25.38 million yuan, reflecting a substantial growth of 140.35% [1] - The company was previously in a loss position in 2024 but has since returned to a growth trajectory under new leadership [1] Market Trends - The CRO industry is undergoing a transformation, with a shift from price competition to a focus on technical capabilities and innovative solutions [2][5] - The average FTE price has decreased from over 500,000 yuan to around 400,000 yuan, with some companies even lower [2] - The new modality drug development is becoming a key growth driver for the CRO industry, with significant market opportunities emerging [5] Strategic Initiatives - The company is focusing on new modality business and has formed multiple strategic partnerships, including collaborations in small nucleic acid delivery and ion channel drug development [4] - The customer base is evolving, with a return of multinational clients alongside a focus on small biotech firms [4] - The company is integrating AI technology into drug development, having completed local deployment of AI for drug efficacy evaluation [4] Future Outlook - The company has set a target to achieve a revenue of 2.5 billion yuan and a net profit of no less than 200 million yuan by 2027, with new modality business seen as a key growth engine [5] - The active development of new modality drugs is expected to create new growth spaces for the CRO industry, as highlighted by BCG's insights on the future of biopharmaceuticals [5] - The company is positioned to transition from a follower to a leader in the new modality drug market, leveraging its long-term technical accumulation and project experience [5]

Core Viewpoint - The stock of Ruizhi Pharmaceutical has shown significant growth this year, with a notable increase in both share price and trading volume, indicating strong market interest and investor confidence [2][3]. Group 1: Stock Performance - As of September 9, Ruizhi Pharmaceutical's stock price increased by 2.18%, reaching 14.05 CNY per share, with a trading volume of 1.83 billion CNY and a market capitalization of 69.96 billion CNY [1]. - Year-to-date, the stock price has risen by 118.85%, with recent trading performance showing an 8.58% increase over the last five trading days, an 11.24% increase over the last 20 days, and a 20.70% increase over the last 60 days [2]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on July 29, where it recorded a net purchase of 1.65 billion CNY [2]. Group 2: Financial Performance - For the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 5.34 billion CNY, reflecting a year-on-year growth of 14.75%, while the net profit attributable to shareholders was 25.38 million CNY, marking a substantial increase of 140.35% [3]. - The company has cumulatively distributed 1.80 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [4]. Group 3: Shareholder and Ownership Structure - As of August 8, the number of shareholders for Ruizhi Pharmaceutical was 52,500, a decrease of 18.89% from the previous period, while the average number of tradable shares per person increased by 23.28% to 9,038 shares [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 24.33 million shares, with no change in the number of shares held compared to the previous period [4]. Group 4: Business Overview - Ruizhi Pharmaceutical, established on January 26, 2000, and listed on December 22, 2010, is primarily engaged in pharmaceutical research and production outsourcing services, with 99.06% of its revenue derived from these services [2]. - The company operates within the pharmaceutical and biotechnology sector, focusing on medical services and research outsourcing, and is associated with concepts such as CRO, innovative drugs, biopharmaceuticals, AI medicine, and cancer treatment [2].